3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
46
Stomach Neoplasms
10
Neoplasms
10
Colorectal Neoplasms
8
Neoplasm Metastasis
7
HER2-positive Breast Cancer
7
Esophageal Neoplasms
5
Triple Negative Breast Neoplasms
4
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Adenocarcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Meningeal Neoplasms
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Colonic Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urinary Bladder Neoplasms
1
Solid Tumor, Adult
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Interventions
Blood Specimen Collection
5
Liquid Biopsy
2
Folfox protocol
2
Carboplatin
2
pertuzumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Standard of Care
1
Sevoflurane
1
Radiotherapy, Adjuvant
1
Propofol
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Neoadjuvant Therapy
1
Mastectomy, Segmental
1
Gemcitabine
1
Fluorouracil
1
Epirubicin
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Colonography, Computed Tomographic
1
Cisplatin
1
Chemotherapy, Adjuvant
1
Capecitabine
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplastic Cells, Circulating
×
Trastuzumab
×
Clear all
NCT04993014
2021-08-06
HER2Cell
AC Camargo Cancer Center
Phase 2
Recruiting
80 enrolled